Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...
Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 -- Inhibikase Therapeutics, Inc. , a...
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing...
Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund March 26, 2024March 26, 2024 Alterity Therapeutics ...